Analyst call on agreement to acquire TESARO

On Monday, 3 December 2018, GSK announced an agreement to acquire TESARO, an oncology-focused company based in the US. A call for investors and analysts was hosted by Emma Walmsley, Chief Executive Officer, Simon Dingemans, Chief Financial Officer, Dr Hal Barron, Chief Scientific Officer and President R&D, and Luke Miels, President, GSK Global Pharmaceuticals.